论坛系列
2012年首届北京黑色素瘤国际研讨会（2012.11.3-2012.11.4）
2014年第二届黑色素瘤国际研讨会（214.10.18-2014.10.19）
2016年第三届黑色素瘤国际研讨会（2016.10.22-2016.10.23）
2018年第四届黑色素瘤国际会议（2018.8.25-2018.8.26）
临床试验类
Chin J Cancer ResA phase II study of fotem ustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma（2009）
Eur J CancerA randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients （2011）
J Clin OncolPhase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification （2011）
Mol TherA phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma （2012）
Clin Cancer ResPhase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma （2013）
Ann OncolEfficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial （2017）
BMC CancerVemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study（2018）
Transl OncolA phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151) （2019）
J Clin OncolAxitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: An open-label phase IB trial（2019）
Eur J CancerOpen-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma (2020)
Clin Cancer ResSafety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial （2020）
J Immunother CancerTislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study（2020）
J Clin OncolRandomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma（2021）
J Immunother CancerToripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis（2021）
Front OncolOverall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib plus trametinib: Long-term follow-up of a multicenter, single-arm phase IIa trial（2021）
Eur J CancerPalbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway（2021）
Melanoma ResPhase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy（2022）
Ann OncolToripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial（2022）
Clin Cancer ResAtezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase 2 study（2022）
Eur J CancerA first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma（2022）
Front OncolPembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study（2022）
Eur J CancerApatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial（2023）
BMC MedFirst-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRASmutations（2023）
BMC CancerSafety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study（2023）
JAMA OncolCamrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma：The CAP 03 phase 2 nonrandomized clinical trial（2023）
Ann OncolPhase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma（2023）
J Eur Acad Dermatol VenereolPhase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma（2024）InnovationIBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma（2024）Eur J CancerA phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma（2024）Signal Transduct Target TherNeoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial（2024）OncologistFive-year follow-up of POLARIS-01 phase II trial: Toripalimab as salvage monotherapy in Chinese patients with advanced melanoma（2024）ImmunotherapySAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma（2024）J Immunother CancerToripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial（2024）
转化研究类
Clin Cancer ResLarge-scale analysis of KIT aberrations in Chinese patients with melanoma（2011）
J Clin OncolMajor response to Everolimus in melanoma with acquired Imatinib resistance（2012）
Eur J CancerPrevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort（2012）
Clin Cancer ResLarge-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib（2013）
Clin Cancer ResAnalysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR pathway inhibitors（2015）
Eur J CancerGNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis（2016）
Clin Cancer ResFrequent genetic aberrations1 in the CDK4 pathway in acral melanoma indicate the potential for CDK4/6 inhibitors in targeted therapy（2017）
J Clin InvestMNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma（2017）
Clin Cancer ResMAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients：a retrospective study of 2793 cases （2017）
Ann OncolThe natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients（2017）
NaturePAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas（2017）
Eur J CancerAnalysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor（2018）
Clin Cancer ResGenetic aberrations in the CDK4 pathway are associated with innate resistance to 2 PD-1 blockade in Chinese patients with non-cutaneous melanoma（2019）
Eur J CancerIdentification of a functional polymorphism within the 30-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma（2019）
TheranosticsMicroRNA-23a-3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways（2019）
J Exp Clin Cancer ResmiR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy （2019）
J Hematol OncolSafety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients（2019）
Nat CommunWhole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets（2019）
Clin Cancer ResEarly use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy（2021）
NPJ Genom MedRatio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma（2021）
Eur J CancerReal-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma（2021）
J Immunother CancerRadiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort（2021）
Eur J CancerCumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III（2022）
EClinicalMedicineDabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study（2023）
科研成果奖励
中国黑色素瘤个体化治疗模式的初步建立郭军,孔燕,斯璐,迟志宏,崔传亮,盛锡楠,毛丽丽（2013中国抗癌协会科技奖二等奖）
中国黑色素瘤个体化治疗模式的初步建立郭军,孔燕,斯璐,迟志宏,崔传亮,盛锡楠,毛丽丽,李思明（2014中华医学科技奖二等奖）
中国黑色素瘤个体化治疗模式的初步建立郭军,孔燕,斯璐,迟志宏,崔传亮,盛锡楠,毛丽丽,李思明（2014华夏医学科技奖三等奖）
中国黑色素瘤个体化治疗模式的初步建立郭军,孔燕,斯璐,迟志宏,崔传亮,盛锡楠,毛丽丽,李思明（2014北京市科技进步二等奖）
指南/专家共识
中国黑色素瘤诊断治疗共识（2008年第一版）
中国黑色素瘤诊治指南2009版
中国黑色素瘤诊治指南2011版
中国黑色素瘤诊治指南2013版
中国黑色素瘤诊治指南2015版
CSCO黑色素瘤诊疗指南2017
CSCO黑色素瘤诊疗指南2019
CSCO黑色素瘤诊疗指南2020
CSCO黑色素瘤诊疗指南2021
CSCO黑色素瘤诊疗指南2022
CACA中国肿瘤整合诊治指南-黑色素瘤2022
CSCO黑色素瘤诊疗指南2023
CSCO黑色素瘤诊疗指南2024
中国黑色素瘤规范化病理诊断专家共识（2017年版）（李忠武，陆爱萍）
黑色素瘤病理诊断临床实践指南（2021版）（李忠武，陆爱萍，斯璐）
CSCO黑色素瘤诊疗指南解读——前哨淋巴结活检的意义、操作及治疗专家共识（2021）
加微信号：251170937，方便免费咨询和寻找最合适的免费治疗项目
整理者
